Journal Home
Search for

Volume 44, Issue 3, Pages 269-272 (June 2010)


View previous. 9 of 12 View next.

Influence of tachykinin NK2 receptors on intestinal sensitivity and motility in newborn rats

M. Tramontanaa, S. EvangelistabCorresponding Author Informationemail address, S. Giuliania, S. Manzinib, S. Robeletc, V. Girodc, C.A. Maggia

Received 4 November 2009; accepted 9 January 2010. published online 08 February 2010.

Abstract 

The effect of tachykinin neurokinin NK2 receptors activation on intestinal propulsion and colorectal sensitivity was studied in 7–15days old newborn rats.

In a first set of experiments investigating the intestinal transit, the selective NK2 receptor agonist, [βAla8]NKA-(4-10) was used. It produced an increase of the small intestinal transit measured by charcoal test of 54%, that was inhibited in a dose-dependent manner by nepadutant ([N4-(2-acetamido-2-deoxy-β-d-glucopyranosyl)-l-asparaginyl-l-aspartyl-l-tryptophyl-l-phenylalanyl-l-2,3-diaminopropionyl-l-leucyl]-C-4.2-N-3.5-lactam-C-1.6-N-2.1-lactam), a known selective NK2 receptor antagonist, orally administered 2–48h before the challenge with the NK2 receptor agonist. Nepadutant did not affect the basal intestinal propulsion and showed a good oral bioavailability and long duration of action.

In another set of experiments investigating visceral sensitivity, a fixed distension volume of a balloon inserted intrarectally in 14–15days old newborns rats produced abdominal contractions (AC) that were increased after colonic application of acetic acid (50μl, 0.5%). In this latter condition nepadutant, at 0.5 and 2.5mg/kg p.o., significantly reduced the resulting AC. In control rats, untreated with acetic acid, nepadutant did not affect AC evoked by colorectal distension.

These findings show for the first time two models to assess intestinal motility and visceral sensitivity in newborn rats and indicate nepadutant as a valuable tool to assess the role of NK2 receptors in the intestinal propulsive and nociceptive activity in infants.

a Department of Pharmacology, Menarini Ricerche S.p.A., Florence, Italy

b Preclinical Development, Menarini Ricerche S.p.A., Florence, Italy

c Syncrosome, Campus Scientifique de Saint-Jerome, Marseille, France

Corresponding Author InformationCorresponding author. Address: Department of Preclinical Development, Menarini Ricerche S.p.A., Via Sette Santi 1, 50131 Florence, Italy. Tel.: +39 055 5680519; fax: +39 055 5680510.

PII: S0143-4179(10)00006-5

doi:10.1016/j.npep.2010.01.002


View previous. 9 of 12 View next.